journal article·2016-04-26

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

Stefano Fais, Lorraine O’Driscoll, Francesc E. Borras, Edit Buzas, Giovanni Camussi, Francesco Cappello, Joana Carvalho, Anabela Cordeiro da Silva, Hernando Del Portillo, Samir El Andaloussi, Tanja Ficko Trček, Roberto Furlan, An Hendrix, Ihsan Gursel, Veronika Kralj-Iglic, Bertrand Kaeffer, Maja Kosanovic, Marilena E. Lekka, Georg Lipps, Mariantonia Logozzi, Antonio Marcilla, Marei Sammar, Alicia Llorente, Irina Nazarenko, Carla Oliveira, Gabriella Pocsfalvi, Lawrence Rajendran, Graça Raposo, Eva Rohde, Pia Siljander, Guillaume van Niel, M. Helena Vasconcelos, María Yáñez-Mó, Marjo L. Yliperttula, Natasa Zarovni, Apolonija Bedina Zavec, Bernd Giebel

ACS Nano· Volume 10· Issue 4
Publisher page

Abstract

Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Anti-Tumor Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), 00161 Rome, Italy

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland

IVECAT-Group, Germans Trias i Pujol Research Institute (IGTP), and Nephrology Service, Germans Trias i Pujol University Hospital, Campus Can Ruti, 08916 Badalona, Spain

Department of Genetics, Cell- and Immunobiology, Semmelweis University, 1085 Budapest, Hungary

Molecular Biotechnology Center, Department of Medical Sciences, University of Turin, 8 Turin, Italy

Human Anatomy Section, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, and Euro-Mediterranean Institute of Science and Technology, 90133 Palermo, Italy

Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

Institute for Molecular and Cell Biology, Rua Campo Alegre, 4150-180 Porto, Portugal

ICREA at Barcelona Centre for International Health Research (CRESIB), Hospital Clínic de Universitat de Barcelona, 08036 Barcelona, Spain

ICREA at Institut d’Investigació Germans Trias i Pujol (IGTP), 08916 Badalona, Spain

Department of Laboratory Medicine, Karolinska Institutet, 17177 Stockholm, Sweden

Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX13QX, United Kingdom

Sandoz Biopharmaceuticals−Lek Pharmaceuticals d.d., Mengeš, Slovenia

Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy

Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, 9000 Gent, Belgium

Science Faculty, Molecular Biology and Genetics Department, THORLAB- Therapeutic Oligonucleotide Research Lab, Bilkent University, 06800 Bilkent, Turkey

Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, 1000 Ljubljana, Slovenia

UMR-1280, INRA, and University of Nantes, 44300 Nantes, France

Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, Univeristy of Belgrade, 11000 Belgrade, Serbia

Chemistry Department, University of Ioannina, 45110 Ioannina, Greece

University of Applied Sciences and Arts Northwestern Switzerland, Gründenstrasse 40, 4132 Muttenz, Switzerland

Prof. Ephraim Katzir Department of Biotechnology Engineering, ORT Braude College, Karmiel 2161002, Israel

Dept. of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital−The Norwegian Radium Hospital, 0379 Oslo, Norway

Institute for Environmental Health Sciences and Hospital Infection Control, Medical Center University of Freiburg, 79106 Freiburg am Breisgau, Germany

Department of Pathology and Oncology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal

References (100+)

Show source-provided references
1. ftp://ftp.cordis.europa.eu/pub/etp/docs/swd-2013-strategy-etp-2020_en.pdf(Accessed December 21, 2015) .
2. http://www.etp-nanomedicine.eu/public/press-documents/publications/etpn-publications/etpn-white-paper-H2020(Accessed December 21, 2015) .
3. ftp://ftp.cordis.europa.eu/pub/nanotechnology/docs/nanomedicine_bat_en.pdf(Accessed December 21, 2015) .
4. 10.3402/jev.v4.2706610.3402/jev.v4.27066 ↗
5. 10.1016/j.biocel.2011.10.00510.1016/j.biocel.2011.10.005 ↗
6. 10.3402/jev.v4.3008710.3402/jev.v4.30087 ↗
7. 10.1021/ar200019c10.1021/ar200019c ↗
8. 10.1056/NEJM19910425324170210.1056/NEJM199104253241702 ↗
9. 10.1093/jncimonographs/lgs03510.1093/jncimonographs/lgs035 ↗
10. 10.1056/NEJMoa081069610.1056/NEJMoa0810696 ↗
11. 10.1056/NEJMcp110364210.1056/NEJMcp1103642 ↗
12. 10.1373/clinchem.2008.10560110.1373/clinchem.2008.105601 ↗
13. 10.1056/NEJMoa081008410.1056/NEJMoa0810084 ↗
14. 10.1016/S1470-2045(08)70112-810.1016/S1470-2045(08)70112-8 ↗
15. 10.1186/1741-7015-12-2610.1186/1741-7015-12-26 ↗
16. 10.1016/j.eururo.2008.01.03410.1016/j.eururo.2008.01.034 ↗
17. 10.1186/1479-5876-7-410.1186/1479-5876-7-4 ↗
18. Mizutani K. · Anticancer Res. · 2014 · 34 · 3419
19. 10.3389/fonc.2014.0026710.3389/fonc.2014.00267 ↗
20. 10.1371/journal.pone.000521910.1371/journal.pone.0005219 ↗
21. 10.1038/nature1458110.1038/nature14581 ↗
22. 10.2478/raon-2013-003710.2478/raon-2013-0037 ↗
23. 10.1038/nm.275310.1038/nm.2753 ↗
24. 10.1002/cncr.2949910.1002/cncr.29499 ↗
25. 10.1371/journal.pone.004673710.1371/journal.pone.0046737 ↗
26. 10.1038/nrurol.2014.30110.1038/nrurol.2014.301 ↗
27. 10.1002/prca.20120013410.1002/prca.201200134 ↗
28. 10.1371/journal.pone.013047210.1371/journal.pone.0130472 ↗
29. 10.1183/09031936.03.0004170310.1183/09031936.03.00041703 ↗
30. 10.1136/thx.2009.13202710.1136/thx.2009.132027 ↗
31. 10.1016/j.jaci.2012.11.03910.1016/j.jaci.2012.11.039 ↗
32. 10.1002/gcc.2218110.1002/gcc.22181 ↗
33. 10.2500/ajra.2011.25.357310.2500/ajra.2011.25.3573 ↗
34. 10.5410/wjcu.v3.i2.6610.5410/wjcu.v3.i2.66 ↗
35. 10.3389/fimmu.2015.0000610.3389/fimmu.2015.00006 ↗
36. 10.3402/jev.v4.2736910.3402/jev.v4.27369 ↗
37. 10.1371/journal.pone.009609410.1371/journal.pone.0096094 ↗
38. 10.1002/pmic.20100044310.1002/pmic.201000443 ↗
39. 10.3389/fimmu.2015.0005010.3389/fimmu.2015.00050 ↗
40. 10.1038/nrn.2015.2910.1038/nrn.2015.29 ↗
41. 10.1016/j.jstrokecerebrovasdis.2015.06.01810.1016/j.jstrokecerebrovasdis.2015.06.018 ↗
42. 10.1073/pnas.060383810310.1073/pnas.0603838103 ↗
43. 10.3390/ijms1603480010.3390/ijms16034800 ↗
44. 10.1074/jbc.M111.32461610.1074/jbc.M111.324616 ↗
45. 10.1074/jbc.M114.57721310.1074/jbc.M114.577213 ↗
46. 10.1002/ana.2423510.1002/ana.24235 ↗
47. 10.1002/ana.2362710.1002/ana.23627 ↗
48. 10.1038/nm.299410.1038/nm.2994 ↗
49. 10.3389/fmicb.2015.0113210.3389/fmicb.2015.01132 ↗
50. 10.3402/jev.v3.2504010.3402/jev.v3.25040 ↗
51. 10.1016/j.pain.2014.04.02910.1016/j.pain.2014.04.029 ↗
52. 10.1016/j.medmal.2012.05.01110.1016/j.medmal.2012.05.011 ↗
53. 10.1016/j.jprot.2013.03.01210.1016/j.jprot.2013.03.012 ↗
54. 10.1016/j.celrep.2015.09.05810.1016/j.celrep.2015.09.058 ↗
55. 10.1093/rheumatology/kel32910.1093/rheumatology/kel329 ↗
56. 10.1007/BF0216941310.1007/BF02169413 ↗
57. 10.1021/pr200711w10.1021/pr200711w ↗
58. 10.1039/c2mb05455h10.1039/c2mb05455h ↗
59. 10.1084/jem.183.3.116110.1084/jem.183.3.1161 ↗
60. 10.1038/nm0598-59410.1038/nm0598-594 ↗
61. 10.1186/1479-5876-3-1010.1186/1479-5876-3-10 ↗
62. 10.1186/1479-5876-3-910.1186/1479-5876-3-9 ↗
63. 10.1097/CJI.0b013e3181fe535b10.1097/CJI.0b013e3181fe535b ↗
64. 10.1080/2162402X.2015.107100810.1080/2162402X.2015.1071008 ↗
65. 10.1128/IAI.72.7.4127-4137.200410.1128/IAI.72.7.4127-4137.2004 ↗
66. 10.1016/j.micinf.2007.07.00210.1016/j.micinf.2007.07.002 ↗
67. 10.1016/j.vaccine.2009.01.02210.1016/j.vaccine.2009.01.022 ↗
68. 10.1371/journal.pone.002658810.1371/journal.pone.0026588 ↗
69. 10.1155/2015/83205710.1155/2015/832057 ↗
70. 10.1146/annurev.micro.091208.07341310.1146/annurev.micro.091208.073413 ↗
71. 10.1038/nri383710.1038/nri3837 ↗
72. 10.1016/j.vaccine.2009.04.07110.1016/j.vaccine.2009.04.071 ↗
73. 10.1007/s40259-013-0029-210.1007/s40259-013-0029-2 ↗
74. 10.1038/mt.2008.110.1038/mt.2008.1 ↗
75. 10.1089/hum.2015.07210.1089/hum.2015.072 ↗
76. 10.1038/leu.2014.4110.1038/leu.2014.41 ↗
77. 10.1016/j.semcdb.2015.03.00110.1016/j.semcdb.2015.03.001 ↗
78. 10.1016/j.imlet.2015.06.00710.1016/j.imlet.2015.06.007 ↗
79. 10.1681/ASN.200807079810.1681/ASN.2008070798 ↗
80. 10.5966/sctm.2015-007810.5966/sctm.2015-0078 ↗
81. 10.1186/s13287-015-0150-x10.1186/s13287-015-0150-x ↗
82. 10.1182/blood-2007-03-07870910.1182/blood-2007-03-078709 ↗
83. Ranghino A. · Int. J. Immunopathol. Pharmacol. · 2012 · 25 · 7510.1177/039463201202500110 ↗
84. 10.1038/ki.2012.10510.1038/ki.2012.105 ↗
85. 10.1002/eji.20124290910.1002/eji.201242909 ↗
86. 10.1016/j.bbrc.2013.07.04410.1016/j.bbrc.2013.07.044 ↗
87. 10.1016/j.immuni.2014.05.01910.1016/j.immuni.2014.05.019 ↗
88. 10.3389/fimmu.2014.0043310.3389/fimmu.2014.00433 ↗
89. 10.1038/ncomms648810.1038/ncomms6488 ↗
90. 10.1016/j.ijpharm.2006.07.04610.1016/j.ijpharm.2006.07.046 ↗
91. 10.2217/17435889.2.3.37510.2217/17435889.2.3.375 ↗
92. 10.1007/978-1-4939-3112-5_2310.1007/978-1-4939-3112-5_23 ↗
93. 10.1016/j.jconrel.2015.09.03110.1016/j.jconrel.2015.09.031 ↗
94. 10.1038/nrd397810.1038/nrd3978 ↗
95. 10.1002/pros.2285310.1002/pros.22853 ↗
96. 10.1038/cr.2014.4410.1038/cr.2014.44 ↗
97. 10.18632/oncotarget.519210.18632/oncotarget.5192 ↗
98. 10.1016/j.jconrel.2015.03.03310.1016/j.jconrel.2015.03.033 ↗
99. 10.1016/j.addr.2012.08.00810.1016/j.addr.2012.08.008 ↗
100. 10.1002/mds.2597810.1002/mds.25978 ↗